Part of the charlotte-mecklenburg hospital authority (north carolina)
Clinical Trials
118
3 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1834
Active, not recruiting
1
0.8%
Completed
80
67.8%
Not yet recruiting
2
1.7%
Recruiting
6
5.1%
Suspended
1
0.8%
Terminated
20
16.9%
Unknown
2
1.7%
Withdrawn
6
5.1%
No approval data available
- The MIND diet, which combines elements of Mediterranean and DASH diets, has more research supporting its role in dementia prevention than any other dietary approach currently studied. - A 2024 Lancet report estimated that 45% of dementia cases worldwide are caused by modifiable risk factors, with diet playing a significant role alongside exercise, sleep, and social engagement. - Key MIND diet foods include leafy greens, berries, nuts, olive oil, and fatty fish; one study found daily leafy green consumption was associated with brain function equivalent to being 11 years younger. - Experts emphasize that sustainable long-term habits matter more than perfection, and diet works best when combined with physical activity, adequate sleep, and social connection.
- Bispecific T-cell engagers demonstrate variable effectiveness in multiple myeloma depending on treatment setting, with talquetamab showing promise as pre-CAR T therapy to reduce cytokine release syndrome and neurotoxicity. - These agents produce deeper and more durable responses compared to standard therapies but carry increased infection risk, particularly with BCMA-targeting bispecifics. - Approximately 30% of patients fail to respond to bispecific treatment, potentially due to host immune system factors, patient fitness, and cancer cell soluble BCMA levels. - Researchers are exploring fixed-duration treatment strategies followed by observation periods to mitigate prolonged adverse effects associated with infections.
- Intensive blood pressure management for 3.3 years significantly reduces the risk of mild cognitive impairment and dementia in adults with hypertension. - The SPRINT trial's follow-up study reveals that cognitive benefits persist for up to seven years, even after the intensive treatment is discontinued. - Maintaining a systolic blood pressure target of 120 mmHg shows a 13% reduction in mild cognitive impairment compared to the standard target of 140 mmHg. - Findings emphasize intensive blood pressure control as a crucial strategy for preventing cognitive decline and promoting healthy aging.
• A new study suggests GLP-1 receptor agonists and SGLT2 inhibitors may significantly reduce the risk of heart attacks and death in stroke survivors. • SGLT2 inhibitors were associated with a 67% lower risk of second strokes, offering a potential preventative measure for recurrent events. • The research highlights the potential of these diabetes and weight loss drugs in preventing further cardiovascular events in individuals who have experienced ischemic stroke. • Findings indicate a substantial reduction in death rates among stroke survivors taking these medications, from 54% to 11.8%.
